The effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women.
The actual role of Bax protein as a prognostic biomarker that predicts response to therapy remains unclear. The objective of this study was to evaluate the effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women. Twenty postmenopausal patients with operable stage II, estrogen receptor-positive, infiltrating ductal breast carcinoma were treated with oral raloxifene at a dose of 60 mg/day for a period of 28 days before definitive surgery. Tumor samples were obtained by incisional biopsy at the time of diagnosis and again at the time of definitive surgical treatment. Immunohistochemical evaluation of Bax expression was assessed semiquantitatively based on the fraction of stained tumor cells and intensity of staining. McNemar's test was used to analyze data (P < 0.05). Eleven of the 20 (55%) patients were classified as positive for Bax expression before raloxifene treatment, whereas 9(45%) were classified as positive after raloxifene treatment (P = 0.479). In conclusion, raloxifene did not alter Bax expression significantly in estrogen receptor-positive breast carcinomas of postmenopausal women.
Department of Gynecology, Division of Mastology, Getúlio Vargas Hospital, Universidade Federal do Piauí, Teresina, Piauí, Brazil. pvlcosta@ig.com.br
Pedro Vitor
PV
Lopes-Costa
Alesse Ribeiro
AR
dos Santos
Benedito Borges
BB
da Silva
D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D001706:Biopsy / Q000379:methods; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D017698:Postmenopause; D011379:Prognosis; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000494:pharmacology*; D011960:Receptors, Estrogen / Q000378:metabolism; D016896:Treatment Outcome; D051028:bcl-2-Associated X Protein / Q000378:metabolism*
C494826:BAX protein, human; D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D051028:bcl-2-Associated X Protein; D020849:Raloxifene Hydrochloride